

## Ebola virus-like particles (EBOV VLP)

**Catalog #: 0550-001**

**Lot #: 1506002**

**Description:** Virus-like Particles (VLP's) expressing recombinant Ebola virus (EBOV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). These VLP's are produced in Sf9 insect cells through infection with a recombinant baculovirus.


**Storage:** 2-3 weeks at -20°C, -80°C long term

**Size:** 1 mg of protein supplied in PBS (supplemented with glycerol, arginine and glutamic acid) at a concentration of **1.54 mg/mL**.

**Relevance:** Since these VLP's mimic Ebola virus but do not contain genetic material, thus are not infectious and make an ideal candidate as a vaccine and also as a tool to enhance filovirus research.

**Related Products:** IBT provides a wide array of anti-filovirus specific antibodies and other infectious disease reagents. Please see our website, [www.ibtbioservices.com](http://www.ibtbioservices.com) for more details.

### Western Blot Detection



Western Blot was used to confirm the presence of EBOV-specific GP, NP and VP40 in the VLP. VLP sample was heat-denatured under reducing condition and loaded at 1 µg/lane.

(A) GP was detected as a broadly-diffused band 60-110 kDa using 1 µg/mL of anti-EBOV GP rabbit Pab (cat# 0301-015)

(B) NP was detected as a single sharp band at ~90 kDa using 1 µg/mL of anti-EBOV NP rabbit Pab (cat# 0301-012)

(C) VP40 was detected as a single sharp band at ~40 kDa using 1 µg/mL of anti-EBOV VP40 rabbit Pab (cat# 0301-010)

**Intended for research use only, not for human, therapeutic, or diagnostic applications.**

*The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.*

**Copyright 2015. Integrated BioTherapeutics, Inc. All rights reserved.**